| Followers | 5 |
| Posts | 593 |
| Boards Moderated | 0 |
| Alias Born | 06/11/2010 |
Tuesday, August 08, 2017 3:20:44 AM
I like your intuitions on
picking a good investment, AND your dogged stubborness in sticking
with your convictions. It's not a guarantee that it will work
out, BUT is sure did with Ariad, and I believe it will also
have similar results here (minus the drama there).
I cannot think of another biotech where the probability
for a favorable outcome is as good as AUPH. The people
running the show are top notch, have deep experience in
both the specific science (LN related issues), and the
business acumen based on a very similar (almost
the same) medical and business situation.
While it might take two years for approval, I think we'll
see upward movement before that, after all, Aurinia does
have other indications for Voc. and potential for deal-making.
Good luck to you and fellow longs,
zzaatt/amp
PS: This two year (blinded) wait seems pretty grotesque, given the
strong results in P2 and the fact that it will cost the lives
of thousands of very desperate patients. I always had a
profound contempt for the corrupt, hide-bound bureaucracy
known as the FDA and I'm hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible,
it certainly should be, if the goal is to help sick people.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=133437830
".... hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible, ...."
Good point- what are they waiting for? Why not approve treatment today and do a Phase 4 instead? VOC has been thoroughly tested by more than 2000 people and shown to be very safe, it's shown to be effective as well so the downside is either very small or non-existent.
Seems stupid when the upside of helping suffering people (saving lives) is considered. Hate the bureaucratic overkill rules and regs of gov't.
No wonder the average cost of bringing a new drug to market in the USA is something like 2.6 billion and takes years and years.
There has to be a better way.
http://investorshub.advfn.com/boards/replies.aspx?msg=133437830
Recent AUPH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:05:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:04:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:03:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:10:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:07:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 01:20:50 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 05/11/2026 01:15:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 12:23:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:22:07 PM
- Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress • Business Wire • 05/07/2026 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 08:31:08 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 04/13/2026 11:27:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:56:49 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:18 PM
- Kezar Life Sciences shares surge after Aurinia announces acquisition • IH Market News • 03/30/2026 03:07:34 PM
- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right • Business Wire • 03/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:03:47 PM
- Aurinia Announces Management Transition • Business Wire • 03/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:25:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 11:06:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 11:02:50 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress • Business Wire • 02/26/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:08:05 PM
